NasdaqCM - Nasdaq Real Time Price • USD
Nektar Therapeutics (NKTR)
As of 11:29 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | -0.19 | -0.19 | -0.88 | -0.71 |
| Low Estimate | -0.22 | -0.22 | -1.21 | -1 |
| High Estimate | -0.17 | -0.15 | -0.65 | -0.31 |
| Year Ago EPS | -0.73 | -0.27 | -1.45 | -0.88 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | 15.34M | 15.34M | 67.51M | 62.27M |
| Low Estimate | 5.4M | 5.4M | 22.2M | 22.9M |
| High Estimate | 20.62M | 20.62M | 85.33M | 81.92M |
| Year Ago Sales | -- | 20.5M | 90.12M | 67.51M |
| Sales Growth (year/est) | -- | -25.20% | -25.10% | -7.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.25 | -0.28 | -0.2 | -0.21 |
| EPS Actual | -0.73 | -0.27 | -0.24 | -0.22 |
| Difference | -0.48 | 0.01 | -0.04 | -0.01 |
| Surprise % | -192.00% | 3.60% | -20.00% | -4.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.19 | -0.19 | -0.88 | -0.71 |
| 7 Days Ago | -0.19 | -0.19 | -0.88 | -0.71 |
| 30 Days Ago | -0.19 | -0.19 | -0.88 | -0.71 |
| 60 Days Ago | -0.16 | -0.15 | -0.76 | -0.54 |
| 90 Days Ago | -0.15 | -0.14 | -0.69 | -0.53 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | NKTR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 74.00% | -- | -- | 1.30% |
| Next Qtr. | 29.60% | -- | -- | 10.60% |
| Current Year | 39.30% | -- | -- | 5.10% |
| Next Year | 19.30% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -7.30% | -- | -- | 11.21% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Jefferies: Hold to Hold | 3/6/2024 |
| Upgrade | TD Cowen: Market Perform to Outperform | 11/9/2023 |
| Reiterates | Mizuho: Neutral | 8/7/2023 |
| Upgrade | Jefferies: Underperform to Hold | 5/10/2023 |
| Maintains | Oppenheimer: Perform | 3/6/2023 |
| Maintains | Goldman Sachs: Sell | 2/27/2023 |
Related Tickers
KTRA Kintara Therapeutics, Inc.
0.1212
+6.04%
FGEN FibroGen, Inc.
1.1700
+2.63%
KPTI Karyopharm Therapeutics Inc.
1.1350
+0.44%
SGMO Sangamo Therapeutics, Inc.
0.5538
+8.57%
BLUE bluebird bio, Inc.
1.0200
+7.00%
JSPR Jasper Therapeutics, Inc.
23.18
+2.93%
VERU Veru Inc.
1.4100
+11.02%
CMRX Chimerix, Inc.
0.9050
-0.97%
KZR Kezar Life Sciences, Inc.
0.8356
+1.65%
MCRB Seres Therapeutics, Inc.
0.6902
+10.50%